Loading viewer...
conference
Format: PDF conference
ESSA Pharma presented at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit in September 2021. The company is developing first-in-class N-terminal domain (NTD) inhibitors of the androgen receptor for treating prostate and hormone-driven cancers, with EPI-7386 in Phase 1 clinical development. With $202M in cash reserves, ESSA is advancing its pipeline across resistant metastatic castration-resistant prostate cancer and other indications.
presentation
conference
14 Pages
Wells Fargo
EFTISARC-NEO Trial: Pembrolizumab + Eftilagimod Neoadjuvant STS 2024
conferenceconference
1 Pages
Maria Sklodowska-Curie National Research Institute of Oncology
Summit Wireless (WISA) 2021 Rocky Mountain Microcap Conference Presentation
conferenceconference
24 Pages
Summit Wireless Technologies, Inc.